Table 1. Clinical details and antibody... | American Society of Hematology

Table 1.

Clinical details and antibody status of patients with ALK-positive ALCL

Patient	Stage	Time of plasma collection	Follow-up^†	Plasma reactivity with transfectants^*			In vitro kinase assay (kd)
Patient	Stage	Time of plasma collection	Follow-up^†	Vector–NPM-ALK	Vector–ALK	Vector only	In vitro kinase assay (kd)
1	IIA	Pretreatment	CR (15 mo)	+ (high titer)	+	−	80
2	IV	2 mo posttreatment	PD (12 mo)	+ (low titer)	−	−	80
3	IVB	Pretreatment	Died (10 mo)	+ (low titer)	+	−	80
4	IVB	Pretreatment	Died (18 mo)	+ (low titer)	+	−	80
5	IV	102 mo posttreatment	CR (120 mo)	+ (low titer)	+/−	−	80
6	IIA	Pretreatment	CR (25 mo)	+ (high titer)	+	−	80
7	IIIB	Pretreatment	CR (31 mo)	+ (high titer)	+	−	80
8	IVB	Pretreatment	PD (9 mo)	+ (high titer)	+	−	80
9	IVB	2 mo posttreatment	CR (13 mo)	+ (high titer)	+	−	80
10	IB	Pretreatment	CR (13 mo)	+ (high titer)	+	−	80
11	IIA	Pretreatment	CR (8 mo)	+ (high titer)	+	−	ND

Patient	Stage	Time of plasma collection	Follow-up^†	Plasma reactivity with transfectants^*			In vitro kinase assay (kd)
Patient	Stage	Time of plasma collection	Follow-up^†	Vector–NPM-ALK	Vector–ALK	Vector only	In vitro kinase assay (kd)
1	IIA	Pretreatment	CR (15 mo)	+ (high titer)	+	−	80
2	IV	2 mo posttreatment	PD (12 mo)	+ (low titer)	−	−	80
3	IVB	Pretreatment	Died (10 mo)	+ (low titer)	+	−	80
4	IVB	Pretreatment	Died (18 mo)	+ (low titer)	+	−	80
5	IV	102 mo posttreatment	CR (120 mo)	+ (low titer)	+/−	−	80
6	IIA	Pretreatment	CR (25 mo)	+ (high titer)	+	−	80
7	IIIB	Pretreatment	CR (31 mo)	+ (high titer)	+	−	80
8	IVB	Pretreatment	PD (9 mo)	+ (high titer)	+	−	80
9	IVB	2 mo posttreatment	CR (13 mo)	+ (high titer)	+	−	80
10	IB	Pretreatment	CR (13 mo)	+ (high titer)	+	−	80
11	IIA	Pretreatment	CR (8 mo)	+ (high titer)	+	−	ND

Weak nuclear labeling was observed with all plasma samples at 1:100 dilution. This labeling disappeared on further dilution.

Plasma immunoreactivity with transfected cells: low titer, 1:100 dilution or less; high titer, 1:750 to 1:6750.

PD indicates progressive disease; CR, complete remission.